Multi-Epitope Immunogen Design for Neurodegenerative Disease Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and other neurodegenerative disorders, such as Alzheimer's, lack effective vaccines that can generate targeted immune responses to misfolded proteins like amyloid-β, tau, and α-synuclein, leading to progressive neuronal loss and cognitive decline.
Innovation Solution
Development of immunogenic compositions comprising specific B cell and T helper epitopes from amyloid-β, tau, and α-synuclein, combined with a MultiTEP platform to induce both cellular and humoral immune responses, which are administered to generate therapeutic antibodies and reduce protein aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then disease progression is managed, but effective vaccines that can generate targeted immune responses to misfolded proteins are lacking
Solution Approach 1:
The patent divides the immunogen into distinct functional segments: region A containing B cell epitopes (residues 1-11 of amyloid-β, residues 2-18 of tau, residues 36-69 of α-synuclein) and region B containing T helper cell epitopes (PADRE and other foreign epitopes). This segmentation allows each region to perform its specific immunological function independently while working together to generate a comprehensive immune response.
Solution Approach 2:
The patent creates a composite immunogen structure that combines multiple epitope types from different proteins (amyloid-β, tau, α-synuclein) with foreign T helper epitopes in a single molecular construct. This composite approach enables simultaneous targeting of multiple neurodegenerative disease markers while leveraging both humoral and cellular immune pathways.
2Reliability
If immunogenic compositions with specific B cell and T helper epitopes are developed, then targeted immune responses are induced, but the complexity of the composition increases
Solution Approach 1:
The patent merges multiple epitope sequences into a single fused immunogen molecule where region A (B cell epitopes) is directly coupled to region B (T helper epitopes). This merging creates a unified construct that can be produced as a single recombinant protein, simplifying manufacturing while maintaining the complexity needed for targeted immune response.
Solution Approach 2:
The patent designs region B to contain multiple foreign T helper epitopes (PADRE, P23, P32, P21, P30, P2, HBVnc, HbsAg, MT, P7, P17, P28) that can bind to various MHC class II molecules across different human populations. This universal design allows the single immunogen composition to elicit T helper responses in diverse individuals, reducing the need for population-specific vaccine variants.
3Object-affected harmful factors
If therapeutic antibodies are generated to reduce protein aggregation, then neurotoxicity is inhibited, but the ability to prevent cognitive decline requires sustained immune response
Solution Approach 1:
The patent incorporates multiple T helper epitopes in region B that can continuously stimulate CD4+ T cell responses, which in turn provide ongoing help to B cells for antibody production. This continuous stimulation ensures sustained levels of therapeutic antibodies against amyloid-β, tau, and α-synuclein, maintaining long-term protection against neurotoxicity and cognitive decline.
Solution Approach 2:
The vaccine design creates a feedback loop where T helper cells activated by region B epitopes produce cytokines and provide co-stimulation to B cells specific for region A epitopes. This feedback mechanism ensures that antibody production is regulated by the immune system's own monitoring mechanisms, allowing sustained response while preventing excessive activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively induce strong immune responses, reducing amyloid and tau burdens, inhibiting neurotoxicity, and slowing cognitive decline, as demonstrated in animal models, with therapeutic antibodies binding to pathological forms and inhibiting their aggregation.
Implementation Method 1
each at least one immunogen comprises a region A coupled to a region B; wherein region A comprises (i) three copies of amino acid residues 1 to 11 of amyloid-β; (ii) the three copies of (i) and three copies of amino acid residues 2 to 18 of tau; or (iii) the two sets of three copies of (ii) and three copies of amino acid residues 36 to 69 of α-synucelin
Data Source
Figure 1
Figure 2A~2B
Figure 3A~4A
AI summary
Disclosed are compositions, comprising one or more immunogens, wherein each immunogen comprises at least two regions, wherein one region comprises at least one amyloid-β (Aβ) B cell epitope or at least one Tau B cell epitope or at least one α-synuclein B cell epitope or combinations thereof, and a second region comprises at least one foreign T helper cell (Th) epitope, and usually multiple foreign Th epitopes. Methods of making and using the compositions are also disclosed.